An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Study of Axi-cel vs. Chemotherapy in Patients with High-Risk Large B-Cell Lymphoma
Sponsor: Kite Pharma Inc
Enrolling: Male and Female Patients
IRB Number: AAAU4058
U.S. Govt. ID: NCT05605899
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to be manufactured, and then infusing those cells back and assessing the effect on your cancer. The experimental product, axi-cel, is not approved by the US Food and Drug Administration (FDA). Participants in both treatment arms will be followed for up to approximately 5 years after being randomized into a study treatment group (randomly assigned, like the flip of a coin).
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with High-Risk Large B-Cell Lymphoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator